Clinical Trial

Treatment of Refractory Melanoma

Study Description

A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Ipilimumab

4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 1, 4, 7, and 10.

Drug - IMO-2125

IMO-2125 intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 16, 20, and 24.

Drug - Ipilimumab

Ipilimumab administered as 4 doses on Weeks 2, 5, 8, and 11.

Additional Information

Official Study Title

A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

Clinical Trial ID

NCT03445533

ParticipAid ID

Rb41kd